According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

Telix’s next-generation PSMA-PET imaging agent for prostate cancer, Gozellix receives US FDA approves: Melbourne, Australia Monday, March 24, 2025, 17:00 Hrs [IST] Telix, a biop ...

Key Takeaways Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

(RTTNews) - Telix Pharmaceuticals (TLX) announced the FDA has approved its New Drug Application for Gozellix, next-generation PSMA-PET imaging agent for prostate cancer. Gozellix, after ...

Gozellix®, after radiolabeling with 68 Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive ...

One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...

The S&P/ASX 200 Index (ASX: XJO) healthcare stock is charging higher again on Friday following another FDA goal.

Gozellix® builds on the success of Telix’s established PSMA-PET imaging agent, Illuccix®, and will be available alongside the first-generation product, providing choice for customers and ...